The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Open accessAbstract
Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells 2,3, whereas cDC2 are specialized for priming CD4+ T cells 4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms 6-11, including a process whereby CD4+ T cells 'license' cDC1 for CD8+ T cell priming 12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1 Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“cDC1 are critical for antigen cross-presentation required to prime CD8+ T cells for optimal anti-tumor immunity and priming of CD4+ T cells at early stages, partly because cDC1 provides antigen transportation to lymph nodes for processing by cDC2 (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8+ T cells (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, É., Tussiwand, R., & Yona, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3712 · Cited by 1,923
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,454
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Schlitzer, A., McGovern, N. N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A. W. S., See, P., Shin, A., Wasan, P. S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.011 · Cited by 884
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Self-citationInterleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
Williams, M. A., Tyznik, A. J., & Bevan, M. J. (2006) · Nature · doi:10.1038/nature04790 · Cited by 792
Bennett, S. R. M., Carbone, F., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725
Satpathy, A. T., Wumesh, K. C., Albring, J. C., Edelson, B. T., Kretzer, N. M., Bhattacharya, D., Murphy, T. L., & MURPHY, K. M. M. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120030 · Cited by 668
The multifaceted role of CD4+ T cells in CD8+ T cell memory
Laidlaw, B. J., Craft, J. E., & Kaech, S. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.10 · Cited by 657
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J. L., Ruhland, M. K., Kersten, K., Abushawish, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 654
Sun, J. C.-Y., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 644
A Role for CD40 Expression on CD8 + T Cells in the Generation of CD8 + T Cell Memory
Bourgeois, C., Rocha, B., & Tanchot, C. (2002) · Science · doi:10.1126/science.1072615 · Cited by 641
Šedý, J. R., Gavrieli, M., Potter, K. G., Hurchla, M. A., Lindsley, R. C., Hildner, K., Scheu, S., Pfeffer, K., Ware, C. F., Murphy, T. L., et al. (2004) · Nature Immunology · doi:10.1038/ni1144 · Cited by 640
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis
Kohyama, M., Ise, W., Edelson, B. T., Wilker, P. R., Hildner, K., Mejia, C., Frazier, W. A., Murphy, T. L., & Murphy, K. M. (2009) · Nature · doi:10.1038/nature07472 · Cited by 479
Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity
Smith, C. M., Wilson, N. S., Waithman, J., Villadangos, J. A., Carbone, F. R., Heath, W. R., & Belz, G. T. (2004) · Nature Immunology · doi:10.1038/ni1129 · Cited by 448
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 445
Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation
Williams, J. W., Tjota, M. Y., Clay, B. S., Lugt, B. V., Bandukwala, H. S., Hrusch, C. L., Decker, D. C., Blaine, K. M., Fixsen, B. R., Singh, H., et al. (2013) · Nature Communications · doi:10.1038/ncomms3990 · Cited by 415
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A. A., Xiao, Y., Jacobs, H., & Borst, J. G. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 406
The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments
Zhang, J., Czabotar, P. E., Policheni, A. N., Caminschi, I., Wan, S. S., Kitsoulis, S., Tullett, K. M., Robin, A. Y., Brammananth, R., van Delft, M. F., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.009 · Cited by 366
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 354
Design and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A. D., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 348
Robust Anti-Viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions
Eickhoff, S., Brewitz, A., Gerner, M. Y., Klauschen, F., Komander, K., Hemmi, H., Garbi, N., Kaisho, T., Germain, R. N., & Kastenmüller, W. (2015) · Cell · doi:10.1016/j.cell.2015.08.004 · Cited by 337
Huysamen, C., Willment, J. A., Dennehy, K. M., & Brown, G. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709923200 · Cited by 336
Hor, J. L., Whitney, P. G., Zaid, A., Brööks, A. G., Heath, W. R., & Mueller, S. N. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.020 · Cited by 294
Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling
Pasqual, G., Chudnovskiy, A., Tas, J. M. J., Agudelo, M., Schweitzer, L. D., Cui, A., Hacohen, N., & Victora, G. D. (2018) · Nature · doi:10.1038/nature25442 · Cited by 270
Ardouin, L., Luche, H., Chelbi, R., Carpentier, S., Shawket, A., Montañana-Sanchis, F., Maria, C. S., Grenot, P., Alexandre, Y. O., Grégoire, C., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.019 · Cited by 228
Kamphorst, A. O., Guermonprez, P., Dudziak, D., & Nussenzweig, M. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001205 · Cited by 208
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 198
Cryptic activation of an Irf8 enhancer governs cDC1 fate specification
Durai, V., Bagadia, P., Granja, J. M., Satpathy, A. T., Kulkarni, D. H., Davidson, J. T., Wu, R., Patel, S. J., Iwata, A., Liu, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0450-x · Cited by 178
IRF4 Promotes Cutaneous Dendritic Cell Migration to Lymph Nodes during Homeostasis and Inflammation
Bajaña, S., Roach, K., Turner, S., Paul, J. A., & Kovats, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102613 · Cited by 171
Ferris, S. T., Carrero, J. A., Mohan, J. F., Calderon, B., Murphy, K. M., & Unanue, E. R. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.012 · Cited by 164
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Andersen, R. S., Kvistborg, P., Frøsig, T. M., Pedersen, N. W., Lyngaa, R., Bakker, A., Shu, C. J., Straten, P. T., Schumacher, T. N., & Hadrup, S. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.037 · Cited by 132
Virus Subversion of the MHC Class I Peptide-Loading Complex
Lybarger, L. P., Wang, X., Harris, M. R., Virgin, H. W., & Hansen, T. H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00509-5 · Cited by 127
Wu, X., Briseño, C. G., Durai, V., Albring, J. C., Haldar, M., Bagadia, P., Kim, K.-W., Randolph, G. J., Murphy, T. L., & MURPHY, K. M. M. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160600 · Cited by 116
Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival
Lesley, R., Kelly, L. M., Xu, Y., & Cyster, J. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601539103 · Cited by 92
A conditional null allele of the major histocompatibility IA‐beta chain gene
Hashimoto, K., Joshi, S. K., & Koni, P. A. (2002) · genesis · doi:10.1002/gene.10056 · Cited by 87
DC subset–specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo
Lehmann, C. H. K., Barańska, A., Heidkamp, G. F., Heger, L., Neubert, K., Lühr, J. J., Hoffmann, A., Reimer, K. C., Brückner, C., Beck, S., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160951 · Cited by 81
Inducible down-regulation of MHC class I results in natural killer cell tolerance
Bern, M. D., Parikh, B. A., Yang, L., Beckman, D. L., Poursine‐Laurent, J., & Yokoyama, W. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181076 · Cited by 78
Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0138 · Cited by 66
Valdez, Y., Mah, W., Winslow, M. M., Xu, L., Ling, P., & Townsend, S. E. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010898 · Cited by 63
Archambault, A. S., Carrero, J. A., Barnett, L. G., McGee, N. G., Sim, J. E., Wright, J. O., Raabe, T. D., Chen, P., Ding, H., Allenspach, E. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201598 · Cited by 39
Cited by
Sorted by citations
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M., & Reis e Sousa, C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053707 · Cited by 757
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Prete, A. D., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 682
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 511
Metadata
- Authors
- Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., Li, L., Gillanders, W. E., Wu, G. F., Yokoyama, W. M., Murphy, T. L., Schreiber, R. D., & Murphy, K. M.
- Affiliations
- Washington University in St. Louis (US)
- University of California, San Francisco (US)
- Barnes-Jewish Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Nature
- Published
- 2020-08-12
- Volume
- 584
- Issue
- 7822
- Pages
- 624-629
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7469755
- OpenAlex
- W3048641542
- Cited by
- 611
- References
- 50
- Citations by year
- 2026: 112 · 2025: 105 · 2024: 112 · 2023: 127 · 2022: 76 · 2021: 67 · 2020: 12
- FWCI
- 24.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000448, UL1TR002345)
- National Cancer Institute (T32CA009573, R01CA190700, T32CA009621, R01CA248919, P30CA091842)
- National Institute of Allergy and Infectious Diseases (R01AI150297, R01AI129545, T32AI007163, R01AI162643)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK108498, F30DK112466)
- National Institute of Neurological Disorders and Stroke (R01NS106289)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- conventional type 1 dendritic cells, cDC1, CD4+ T cell priming, CD8+ T cell priming, MHC class II, MHC class I, cross-presentation, tumor rejection, antitumor immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Dendritic Cells, Female, Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, CD40 Antigens, Cross-Priming, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
